{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T16:21:06Z","timestamp":1787934066083,"version":"build-2784847793"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Gaucher disease (GD) is an autosomal recessive disorder with a wide range of clinical symptoms that cause abnormal function of parenchymal organs such as liver and spleen in patients. Enzyme replacement therapy, represented by imiglucerase, is a common approach for GD treatment. However, limited efficacy and high cost are important factors restricting its use. Ambroxol has gradually attracted attention due to its ease of administration, safety, and efficacy. However, there is no pharmacoeconomic evaluation of ambroxol for the treatment of GD in China. The cost-effectiveness profile of ambroxol combined with imiglucerase therapy for the treatment of GD, as opposed to imiglucerase monotherapy, needs to be investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to analyze the cost-effectiveness of ambroxol for GD in China from the perspective of the Chinese healthcare system.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We constructed an eight-state Markov model based on the disease characteristics of GD. The Markov cycle was 1 month. The time horizon was 6 years. The willingness-to-pay threshold was chosen to be 1\u20133 times the gross national product (GDP) per capita. The incremental cost-effectiveness ratio (ICER) was calculated from the base-case analysis, and one-way sensitivity analyses and probabilistic sensitivity analyses were performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The ICER value was \u00a5223,726.70, which was between 1 and 3 times GDP per capita. Sensitivity analysis showed that the cost of imiglucerase had a significant effect on ICER as well as demonstrating the stability of the results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Ambroxol combination therapy is a cost-effective regimen compared with imiglucerase monotherapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1568709","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T05:29:28Z","timestamp":1747114168000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-effectiveness analysis of ambroxol for the treatment of Chinese patients with Gaucher disease"],"prefix":"10.3389","volume":"12","author":[{"given":"Yueyang","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"42105","DOI":"10.1074\/jbc.M110.172098","article-title":"Molecular basis of reduced glucosylceramidase activity in the most common Gaucher disease mutant, N370S.","volume":"285","author":"Offman","year":"2010","journal-title":"J Biol Chem."},{"key":"B2","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.semcdb.2004.03.003","article-title":"The pathogenesis of glycosphingolipid storage disorders.","volume":"15","author":"Ginzburg","year":"2004","journal-title":"Semin Cell Dev Biol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1073\/pnas.1400768111","article-title":"Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease.","volume":"111","author":"Mistry","year":"2014","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ymgme.2013.12.005","article-title":"Lysosomal integral membrane protein-2: A new player in lysosome-related pathology.","volume":"111","author":"Gonzalez","year":"2014","journal-title":"Mol Genet Metab."},{"key":"B5","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/brain\/awt367","article-title":"Reduced glucocerebrosidase is associated with increased \u03b1-synuclein in sporadic Parkinson\u2019s disease.","volume":"137","author":"Murphy","year":"2014","journal-title":"Brain."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/humu.23056","article-title":"New directions in gaucher disease.","volume":"37","author":"Horowitz","year":"2016","journal-title":"Hum Mutat."},{"key":"B7","first-page":"1","article-title":"Disease state awareness in Gaucher disease: A Q&A expert roundtable discussion.","volume":"10","author":"Mistry","year":"2012","journal-title":"Clin Adv Hematol Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/ajh.21280","article-title":"A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase.","volume":"83","author":"Weinreb","year":"2008","journal-title":"Am J Hematol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.dld.2020.01.004","article-title":"Liver involvement in Gaucher disease: A practical review for the hepatologist and the gastroenterologist.","volume":"52","author":"Carubbi","year":"2020","journal-title":"Dig Liver Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ymgme.2014.11.008","article-title":"The clinical management of Type 2 Gaucher disease.","volume":"114","author":"Weiss","year":"2015","journal-title":"Mol Genet Metab."},{"key":"B11","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/acn3.292","article-title":"Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study.","volume":"3","author":"Narita","year":"2016","journal-title":"Ann Clin Transl Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/ejp.1538","article-title":"Dual-action ambroxol in treatment of chronic pain in Gaucher disease.","volume":"24","author":"Pawlinski","year":"2020","journal-title":"Eur J Pain."},{"key":"B13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3389\/fcell.2020.00271","article-title":"Small molecule chaperones for the treatment of gaucher disease and GBA1-associated parkinson disease.","volume":"8","author":"Han","year":"2020","journal-title":"Front Cell Dev Biol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"20240970","DOI":"10.1515\/med-2024-0970","article-title":"Cost-effectiveness of ambroxol in the treatment of Gaucher disease type 2.","volume":"19","author":"Milosavljevi\u0107","year":"2024","journal-title":"Open Med (Wars)."},{"key":"B15","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/0272989X9301300409","article-title":"Markov models in medical decision making: A practical guide.","volume":"13","author":"Sonnenberg","year":"1993","journal-title":"Med Decis Making."},{"key":"B16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.bcmd.2010.08.012","article-title":"Type 2 Gaucher disease: Phenotypic variation and genotypic heterogeneity.","volume":"46","author":"Gupta","year":"2011","journal-title":"Blood Cells Mol Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/ije\/dym062","article-title":"Decision modelling for health economic evaluation. A Briggs, M Sculpher, K Claxton.","volume":"36","author":"Caldwell","year":"2007","journal-title":"Int J Epidemiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.braindev.2005.04.005","article-title":"Type 2 Gaucher disease: 15 new cases and review of the literature.","volume":"28","author":"Mignot","year":"2006","journal-title":"Brain Dev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/10245332.2016.1240391","article-title":"Gaucher disease epidemiology and natural history: A comprehensive review of the literature.","volume":"22","author":"Nalysnyk","year":"2016","journal-title":"Hematology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3748\/wjg.v23.i8.1328","article-title":"Pediatric gastrointestinal bleeding: Perspectives from the Italian society of pediatric gastroenterology.","volume":"23","author":"Romano","year":"2017","journal-title":"World J Gastroenterol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e2119","DOI":"10.1212\/WNL.0000000000010605","article-title":"The natural history of type 2 Gaucher disease in the 21st century: A retrospective study.","volume":"95","author":"Roshan Lal","year":"2020","journal-title":"Neurology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e2319336","DOI":"10.1001\/jamanetworkopen.2023.19336","article-title":"Ambroxol as therapy for gaucher disease-ambitious but ambivalent.","volume":"6","author":"Weinreb","year":"2023","journal-title":"JAMA Netw Open."},{"key":"B23","article-title":"China Guidelines for Pharmacoeconomic Evaluations","author":"Guoen","year":"2020"},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","author":"Drummond","year":"2005","journal-title":"Methods for the Economic Evaluations of Health Care Programs."},{"key":"B25","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1177\/0272989X9001000308","article-title":"The CE plane: A graphic representation of cost-effectiveness.","volume":"10","author":"Black","year":"1990","journal-title":"Med Decis Making."},{"key":"B26","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/hec.635","article-title":"Representing uncertainty: The role of cost-effectiveness acceptability curves.","volume":"10","author":"Fenwick","year":"2001","journal-title":"Health Econ."},{"key":"B27","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/lary.26253","article-title":"Surgical management of bilateral vocal fold paralysis: A cost-effectiveness comparison of two treatments.","volume":"127","author":"Naunheim","year":"2016","journal-title":"Laryngoscope."},{"key":"B28","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41430-019-0499-5","article-title":"Quality of life of patients with head and neck cancer after prophylactic percutaneous-gastrostomy.","volume":"74","author":"Hausmann","year":"2019","journal-title":"Eur J Clin Nutr."},{"key":"B29","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/ppul.24308","article-title":"Health-related quality of life in infants and children with interstitial lung disease.","volume":"54","author":"Lauby","year":"2019","journal-title":"Pediatr Pulmonol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/hae.13634","article-title":"Utility valuation of health states for haemophilia and related complications in Europe and in the United States.","volume":"25","author":"Hoxer","year":"2018","journal-title":"Haemophilia."},{"key":"B31","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2147\/PPA.S202773","article-title":"Real-world utilities and health-related quality-of-life data in hemophilia patients in France and the United Kingdom.","volume":"13","author":"Carroll","year":"2019","journal-title":"Patient Prefer Adherence."},{"key":"B32","author":"Jie","year":"2018","journal-title":"Report of Rare Diseases in China."},{"key":"B33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejpn.2021.03.013","article-title":"Early initiation of ambroxol treatment diminishes neurological manifestations of type 3 Gaucher disease: A long-term outcome of two siblings.","volume":"32","author":"Ramad\u017ea","year":"2021","journal-title":"Eur J Paediatr Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"907317","DOI":"10.3389\/fneur.2022.907317","article-title":"Promising effect of high dose ambroxol treatment on neurocognition and motor development in a patient with neuropathic gaucher disease 2.","volume":"13","author":"Aries","year":"2022","journal-title":"Front Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"658","DOI":"10.2174\/1871530321666211119145230","article-title":"Ambroxol chaperone therapy for gaucher disease type i-associated liver cirrhosis and portal hypertension: A case report.","volume":"22","author":"Zhang","year":"2022","journal-title":"Endocrine Metab Immune Disord Drug Targets."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e2319364","DOI":"10.1001\/jamanetworkopen.2023.19364","article-title":"Use of ambroxol as therapy for gaucher disease.","volume":"6","author":"Zhan","year":"2023","journal-title":"JAMA Netw Open."},{"key":"B37","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/jha2.852","article-title":"The use of Ambroxol for the treatment of Gaucher disease: A systematic review.","volume":"5","author":"Abelleyra Lastoria","year":"2024","journal-title":"EJHaem."},{"key":"B38","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1017\/S0266462316000416","article-title":"Scientific and social value judgments for orphan drugs in health technology assessment.","volume":"32","author":"Nicod","year":"2016","journal-title":"Int J Technol Assess Health Care."},{"key":"B39","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/978-3-319-67144-4_13","article-title":"Health technology assessment and appraisal of therapies for rare diseases.","volume":"1031","author":"Iskrov","year":"2017","journal-title":"Adv Exp Med Biol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1568709\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T05:29:29Z","timestamp":1747114169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1568709\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":39,"alternative-id":["10.3389\/fmed.2025.1568709"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1568709","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"article-number":"1568709"}}